C3H/He mice hyperimmune against syngeneic MH134 hepatoma were made by intradermal (id) inoculation of practical tumor cells accompanied by medical resection from the tumor and by repeated id challenges with practical tumor cells. developing tumor, but surfaced in the mice which resisted the first Carboplatin cost tumor problem after the resection of the primary tumor. These results indicate that this emergence of L3T4+ T cell\mediated anti\tumor immunity is usually stage\dependent and the Lyt\2+ T cells represent the main functional subset in the tumor\bearing state, although both subsets of T cells are potentially capable of effecting anti\tumor immunity. The results are discussed in relation to the selective suppression of the L3T4+ but not of Lyt\2+ T cell function in the tumor\hearing state. protective immune T cells in a syngeneic murine tumor system . Gann , 68 , 589 C 601 ( 1977. ). [PubMed] [Google Scholar] 12) Tada T. , Sano H. , Sato S. , Shima J. , Fujiwara H. and Hamaoka T.Tumor\bearing state results in a selective inhibition of L3T4+ but not of Lyt\2+ T cell\mediated immunity Carboplatin cost , J. Leukocyte Biol. , in press . [PMC free article] [PubMed] [Google Scholar] 13) Fukuzawa M. , Fujiwara H. , Yoshioka T. , Itoh K. and Hamaoka T.Tumor\particular Lyt\1+2+ T cells can reject tumor cells without inducing cytotoxic T lymphocyte responses . Transplant. Proc. , 17 , 599 C 605 ( 1985. ). [Google Scholar] 14) Yoshioka T. , Sato S. , Ogata M. , Sakamoto K. , Sano H. , Shima Rabbit polyclonal to BCL2L2 J. , Yamamoto H. , Fujiwara H. and Hamaoka T.Mediation of tumor\neutralizing activity by Lyt\2+ aswell seeing that L3T4+ T cell subsets . Jpn. J. Tumor Res. (Gann) , 79 , 91 C 98 ( 1988. ). [PMC free of charge content] [PubMed] [Google Scholar] 15) Sakamoto K. , Yoshioka T. , Shimizu J. , Sato S. , Nakajima H. , Fujiwara H. and Hamaoka T.Systems for reputation of tumor mediation and antigens of anti\tumor impact by noncytolytic Lyt\2+ T cell subset . Jpn. J. Tumor Res. (Gann) , 79 , 99 C 108 ( 1988. ). [PMC free of charge content] [PubMed] [Google Scholar] 16) Dialynas D. P. , Wilde D. B. , Marrack P. , Pierres A. , Wall structure K. A. , Havran W. , Otten G. , Loken M. R. , Pierres M. , Kappler J. and Fitch F. W.Characterization from the murine antigenic determinant, designated L3T4a, acknowledged by monoclonal antibody GK1.5: expression of L3T4a by functional T cell clones seems to correlate primarily with course II MHC antigen\reactivity . Immunol. Rev. Carboplatin cost , 74 , 29 C 56 ( 1983. ). [PubMed] [Google Scholar] 17) Ogata M. , Shimizu J. , Tsuchida T. , Takai Y. , Fujiwara H. and Hamaoka T.Non\H\2\connected hereditary regulation of cytotoxic replies to hapten\customized syngeneic cells. I. Non\H\2\connected Ir gene defect portrayed on T cells isn’t predetermined on the stage of bone tissue marrow cells . J. Immunol. , 136 , 1178 C 1185 ( 1986. ). [PubMed] [Google Scholar] 18) Aged L. J. , Boyse E. A. , Clarke D. A. and Carswell E. A.Antigenic properties of induced tumors chemically . Ann. N. Y. Acad. Sci. , 101 , 80 C 106 ( 1965. ). [Google Scholar] 19) Boyse E. A. , Aged L. J. and Stockert E.The TL (thymus Carboplatin cost leukemia) antigen: an assessment . em In /em Immunopathology. 4th International Symposium, Monte Carlo , ed. Graber P., editor; and Miescher P. A., editor. , pp . 23 C 40 ( 1965. ). Schwabe & Co. , Basel . [Google Scholar] 20) Stackpole C. W. and Jacobson J. B.Antigenic modulation . em In /em The Handbook of Tumor Immunology. Cellular Get away from Immune Devastation , ed. Waters H., editor. , Vol. 2 , pp . 55 C 159 ( 1978. ). Garland Posting, Inc. , NY . [Google Scholar] 21) Ammann A. J. , Abrams D. , Conant M. , Chudwin D. , Cowen M. , Bolverding P. , Carboplatin cost Lewis B. and Casavant C.Obtained immune system dysfunction in homosexual men: immunologic profiles . Clin. Immunol. Immunopathol. , 27 , 315 C 325 ( 1983. ). [PubMed] [Google Scholar] 22) Street H. C. , Masur H. , Ecgar L. C. , Whalen G. , Rook A. H. and Fauci A. S.Abnormalities of B\cell immunoregulation and activation in sufferers using the acquired immunodeficiency symptoms . N. Engl. J. Med. , 309 , 453 C 458 ( 1983. ). [PubMed] [Google Scholar] 23) Murray H. W. , Rubin B. Y. , Masur H..